Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Jan Philipp Bewersdorf; Zhuoer Xie; Rafael Bejar; Uma Borate; Jacqueline Boultwood; Andrew M. Brunner; Rena Buckstein; Hetty E. Carraway; Jane E. Churpek; Naval G. Daver; Matteo Giovanni Della Porta; Amy E. DeZern; Pierre Fenaux; Maria E. Figueroa; Steven D. Gore; Elizabeth A. Griffiths; Stephanie Halene; Robert P. Hasserjian; Christopher S. Hourigan; Tae Kon Kim; Rami Komrokji; Vijay K. Kuchroo; Alan F. List; Sanam Loghavi; Ravindra Majeti; Olatoyosi Odenike; Mrinal M. Patnaik; Uwe Platzbecker; Gail J. Roboz; David A. Sallman; Valeria Santini; Guillermo Sanz; Mikkael A. Sekeres; Maximilian Stahl; Daniel T. Starczynowski; David P. Steensma; Justin Taylor; Omar Abdel-Wahab; Mina L. Xu; Michael R. Savona; Andrew H. Wei; Amer M. Zeidan

doi:10.1016/j.blre.2023.101072

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M. Brunner, Rena Buckstein, Hetty E. Carraway, Jane E. Churpek, Naval G. Daver, Matteo Giovanni Della Porta, Amy E. DeZern, Pierre Fenaux, Maria E. Figueroa, Steven D. Gore, Elizabeth A. Griffiths, Stephanie Halene, Robert P. Hasserjian, Christopher S. Hourigan, Tae Kon KimRami Komrokji, Vijay K. Kuchroo, Alan F. List, Sanam Loghavi, Ravindra Majeti, Olatoyosi Odenike, Mrinal M. Patnaik, Uwe Platzbecker, Gail J. Roboz, David A. Sallman, Valeria Santini, Guillermo Sanz, Mikkael A. Sekeres, Maximilian Stahl, Daniel T. Starczynowski, David P. Steensma, Justin Taylor, Omar Abdel-Wahab, Mina L. Xu, Michael R. Savona, Andrew H. Wei, Amer M. Zeidan

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.

Original language	English (US)
Article number	101072
Journal	Blood Reviews
Volume	60
DOIs	https://doi.org/10.1016/j.blre.2023.101072
State	Published - Jul 2023
Externally published	Yes

Keywords

Animal models
Genetics
Immunology
MDS
Myelodysplastic syndrome
Novel therapies

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.blre.2023.101072

Fingerprint

Dive into the research topics of 'Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)'. Together they form a unique fingerprint.

Cite this

Bewersdorf, J. P., Xie, Z., Bejar, R., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R., Carraway, H. E., Churpek, J. E., Daver, N. G., Porta, M. G. D., DeZern, A. E., Fenaux, P., Figueroa, M. E., Gore, S. D., Griffiths, E. A., Halene, S., Hasserjian, R. P., Hourigan, C. S., ... Zeidan, A. M. (2023). Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews, 60, Article 101072. https://doi.org/10.1016/j.blre.2023.101072

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). / Bewersdorf, Jan Philipp; Xie, Zhuoer; Bejar, Rafael et al.
In: Blood Reviews, Vol. 60, 101072, 07.2023.

Research output: Contribution to journal › Review article › peer-review

Bewersdorf, JP, Xie, Z, Bejar, R, Borate, U, Boultwood, J, Brunner, AM, Buckstein, R, Carraway, HE, Churpek, JE, Daver, NG, Porta, MGD, DeZern, AE, Fenaux, P, Figueroa, ME, Gore, SD, Griffiths, EA, Halene, S, Hasserjian, RP, Hourigan, CS, Kim, TK, Komrokji, R, Kuchroo, VK, List, AF, Loghavi, S, Majeti, R, Odenike, O, Patnaik, MM, Platzbecker, U, Roboz, GJ, Sallman, DA, Santini, V, Sanz, G, Sekeres, MA, Stahl, M, Starczynowski, DT, Steensma, DP, Taylor, J, Abdel-Wahab, O, Xu, ML, Savona, MR, Wei, AH & Zeidan, AM 2023, 'Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)', Blood Reviews, vol. 60, 101072. https://doi.org/10.1016/j.blre.2023.101072

@article{fb8c8f4ee30e4d2c8aaf38fde52482e5,

title = "Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)",

abstract = "Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.",

keywords = "Animal models, Genetics, Immunology, MDS, Myelodysplastic syndrome, Novel therapies",

author = "Bewersdorf, {Jan Philipp} and Zhuoer Xie and Rafael Bejar and Uma Borate and Jacqueline Boultwood and Brunner, {Andrew M.} and Rena Buckstein and Carraway, {Hetty E.} and Churpek, {Jane E.} and Daver, {Naval G.} and Porta, {Matteo Giovanni Della} and DeZern, {Amy E.} and Pierre Fenaux and Figueroa, {Maria E.} and Gore, {Steven D.} and Griffiths, {Elizabeth A.} and Stephanie Halene and Hasserjian, {Robert P.} and Hourigan, {Christopher S.} and Kim, {Tae Kon} and Rami Komrokji and Kuchroo, {Vijay K.} and List, {Alan F.} and Sanam Loghavi and Ravindra Majeti and Olatoyosi Odenike and Patnaik, {Mrinal M.} and Uwe Platzbecker and Roboz, {Gail J.} and Sallman, {David A.} and Valeria Santini and Guillermo Sanz and Sekeres, {Mikkael A.} and Maximilian Stahl and Starczynowski, {Daniel T.} and Steensma, {David P.} and Justin Taylor and Omar Abdel-Wahab and Xu, {Mina L.} and Savona, {Michael R.} and Wei, {Andrew H.} and Zeidan, {Amer M.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = jul,

doi = "10.1016/j.blre.2023.101072",

language = "English (US)",

volume = "60",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS)

T2 - Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

AU - Bewersdorf, Jan Philipp

AU - Xie, Zhuoer

AU - Bejar, Rafael

AU - Borate, Uma

AU - Boultwood, Jacqueline

AU - Brunner, Andrew M.

AU - Buckstein, Rena

AU - Carraway, Hetty E.

AU - Churpek, Jane E.

AU - Daver, Naval G.

AU - Porta, Matteo Giovanni Della

AU - DeZern, Amy E.

AU - Fenaux, Pierre

AU - Figueroa, Maria E.

AU - Gore, Steven D.

AU - Griffiths, Elizabeth A.

AU - Halene, Stephanie

AU - Hasserjian, Robert P.

AU - Hourigan, Christopher S.

AU - Kim, Tae Kon

AU - Komrokji, Rami

AU - Kuchroo, Vijay K.

AU - List, Alan F.

AU - Loghavi, Sanam

AU - Majeti, Ravindra

AU - Odenike, Olatoyosi

AU - Patnaik, Mrinal M.

AU - Platzbecker, Uwe

AU - Roboz, Gail J.

AU - Sallman, David A.

AU - Santini, Valeria

AU - Sanz, Guillermo

AU - Sekeres, Mikkael A.

AU - Stahl, Maximilian

AU - Starczynowski, Daniel T.

AU - Steensma, David P.

AU - Taylor, Justin

AU - Abdel-Wahab, Omar

AU - Xu, Mina L.

AU - Savona, Michael R.

AU - Wei, Andrew H.

AU - Zeidan, Amer M.

PY - 2023/7

Y1 - 2023/7

N2 - Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.

AB - Biological events that contribute to the pathogenesis of myelodysplastic syndromes/neoplasms (MDS) are becoming increasingly characterized and are being translated into rationally designed therapeutic strategies. Herein, we provide updates from the first International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS) detailing recent advances in understanding the genetic landscape of MDS, including germline predisposition, epigenetic and immune dysregulation, the complexities of clonal hematopoiesis progression to MDS, as well as novel animal models of the disease. Connected to this progress is the development of novel therapies targeting specific molecular alterations, the innate immune system, and immune checkpoint inhibitors. While some of these agents have entered clinical trials (e.g., splicing modulators, IRAK1/4 inhibitors, anti-CD47 and anti-TIM3 antibodies, and cellular therapies), none have been approved for MDS. Additional preclinical and clinical work is needed to develop a truly individualized approach to the care of MDS patients.

KW - Animal models

KW - Genetics

KW - Immunology

KW - MDS

KW - Myelodysplastic syndrome

KW - Novel therapies

UR - http://www.scopus.com/inward/record.url?scp=85150256821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150256821&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2023.101072

DO - 10.1016/j.blre.2023.101072

M3 - Review article

AN - SCOPUS:85150256821

SN - 0268-960X

VL - 60

JO - Blood Reviews

JF - Blood Reviews

M1 - 101072

ER -